| Literature DB >> 34779545 |
Peng-Cheng Wang1,2, Zhi-Qiang Hu1,3, Shao-Lai Zhou1,3, Song-Yang Yu1,3, Li Mao1,3, Sheng Su1,3, Jia Li1,3, Ning Ren1,2,3, Xiao-Wu Huang1,3.
Abstract
Infiltrating immune cells in the tumor microenvironment (TME) influence tumor progression and patient prognosis, making them attractive therapeutic targets for immunotherapy research. A deeper understanding of immune cell distributions in the TME in hepatocellular carcinoma (HCC) is needed to identify interactions among different immune cell types that might impact the effectiveness of potential immunotherapies. We performed multiplex immunohistochemistry using a tissue microarray of samples from 302 patients with HCC to elucidate the spatial distributions of immune cell subpopulations (CD3+ , CD4+ , CD8+ , CD66b+ , and CD68+ ) in HCC and normal liver tissues. We analyzed the associations between different immune subpopulations using Pearson's correlation. G(r) functions, K(r) functions and Euclidean distance were applied to characterize the bivariate distribution patterns among the immune cell types. Cox regression and Kaplan-Meier analysis were used to evaluate the associations between tumor infiltration by different immune cells and patient outcomes after curative surgery. We also analyzed the relationship between the spatial distribution of different immune cell subpopulations with HCC patient prognosis. We found that the immune cell spatial distribution in the HCC TME is heterogeneous. Our study provides a theoretical basis for HCC immunotherapy.Entities:
Keywords: hepatocellular carcinoma; immune cell subpopulations; multiplex immunohistochemistry; prognosis; tumor microenvironment
Mesh:
Substances:
Year: 2021 PMID: 34779545 PMCID: PMC8819352 DOI: 10.1111/cas.15202
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716
Patient clinical information (n = 302)
| Clinicopathologic index | ||
|---|---|---|
| Age (y) | ≤50 | 157 (52.0%) |
| >50 | 145 (48.0%) | |
| Sex | Female | 45 (14.9%) |
| Male | 257 (85.1%) | |
| HBsAg | Negative | 38 (12.6%) |
| Positive | 264 (87.4%) | |
| HCV | Negative | 295 (97.7%) |
| Positive | 7 (2.3%) | |
| AFP (ng/ml) | ≤20 | 90 (29.7%) |
| >20 | 212 (70.3%) | |
| GGT (U/L) | ≤54 | 124 (41.1%) |
| >54 | 178 (58.9%) | |
| Liver cirrhosis | No | 33 (10.9%) |
| Yes | 269 (89.1%) | |
| Tumor size (cm) | ≤5 | 143 (47.4%) |
| >5 | 159 (52.6%) | |
| Tumor number | Single | 255 (84.4%) |
| Multiple | 47 (15.6%) | |
| Microvascular invasion | Absence | 164 (54.3%) |
| Present | 138 (45.7%) | |
| Tumor encapsulation | Complete | 149 (49.3%) |
| None | 153 (50.7%) | |
| Tumor differentiation | I+II | 239 (79.1%) |
| III+IV | 63 (20.9%) | |
| TNM stage | I | 154 (51.0%) |
| II+III | 148 (49.0%) | |
AFP, alpha‐fetoprotein; GGT, gamma glutamyl transferase; TNM, tumor‐node‐metastasis.
FIGURE 1Multiplex immunohistochemistry of primary HCC identifies unique immune cell subtypes. A, Representative multispectral image of HCC tumor sample on tissue microarray. B‐G, The presence of individual markers before spectral mixing: (B) DAPI nuclear marker, (C) CD3, (D) CD4, (E) CD8, (F) CD66b, (G) CD68
FIGURE 2Heterogeneous immune cell subpopulations infiltrating in HCC tissues. A, CD3+ T cells were more abundant in normal tissues than in tumors (**P < .001). B, Percentage of CD4+ T cells within the CD3+ T cell population was lower in normal tissues than in tumors (*P < .05). C, Percentage of CD8+ T cells within the CD3+ T cell population was lower in normal tissues than in tumors (**P <.001). D, Distribution of different immune cell subpopulations within defined groups is shown
FIGURE 3Associations between different immune cell types. A, Intratumoral spatial distribution of CD66b+ cells (neutrophils) was positively correlated with those of CD8+ T cells (R = 0.145, *P < .05), CD68+ cells (macrophages) (R = 0.440, **P < .001), and CD4+ T cells (R = 0.183, **P < .001). B, Cell phenotype map showing the spatial distributions of different immune cell populations. C‐E, G(r) and K(r) functions were used to characterize the observed and expected aggregation patterns between (C) CD66b+ cells and CD68+ cells, (D) CD66b+ cells and CD8+ cells, and (E) CD66b+ cells and CD4+ cells
FIGURE 4Correlation of different immune cells with clinical outcomes in 302 patients with primary HCC. A, Kaplan‐Meier survival analysis showing how intratumoral CD3+, CD4+, CD8+, CD66b+ and CD68+ cells were associated with OS rates and cumulative recurrence rates after surgery. B, Kaplan‐Meier survival analysis showing how the distance between 2 different immune cell subpopulations were associated with OS rates and cumulative recurrence rates after surgery. L‐D (longer distance); S‐D (shorter distance)
Univariate and multivariate analyses of prognostic factors in HCC (n = 302)
| Variable | TTR | OS | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| Univariate analysis | ||||
| Age, y (≤50 vs >50) | 0.918 (0.675‐1.248) | .584 | 0.754 (0.547‐1.040) | .086 |
| Sex (female vs male) | 1.767 (1.082‐2.885) | .023 | 1.640 (0.977‐2.755) | .061 |
| HBsAg (negative vs positive) | 1.118 (0.700‐1.786) | .640 | 1.064 (0.683‐1.658) | .783 |
| AFP, ng/ml (≤20 vs >20) | 1.128 (0.807‐1.576) | .482 | 1.587 (1.091‐2.309) | .016 |
| GGT, U/L (≤54 vs >54) | 1.304 (0.950‐1.789) | .101 | 1.647 (1.174‐2.313) | .004 |
| Liver cirrhosis (no vs yes) | 1.230 (0.723‐2.093) | .444 | 1.305 (0.739‐2.305) | .359 |
| Tumor size, cm (≤5 vs >5) | 1.650 (1.208‐2.254) | .002 | 2.139 (1.530‐2.990) | .000 |
| Tumor number (single vs multiple) | 1.388 (0.922‐2.089) | .116 | 1.605 (1.080‐2.384) | .019 |
| Microvascular invasion (no vs yes) | 1.962 (1.438‐2.676) | .000 | 2.488 (1.795‐3.449) | .000 |
| Tumor encapsulation (complete vs none) | 1.718 (1.260‐2.343) | .001 | 1.747 (1.262‐2.417) | .001 |
| Tumor differentiation (I + II vs III +IV) | 1.198 (0.830‐1.729) | .335 | 1.490 (1.034‐2.145) | .032 |
| TNM stage (I vs II III) | 1.195 (0.879‐1.624) | .256 | 1.482 (1.075‐2.042) | .016 |
| CD3 (low vs high) | 0.713 (0.519‐0.981) | .038 | 0.672 (0.489‐0.925) | .015 |
| CD4 (low vs high) | 0.782 (0.569‐1.073) | .128 | 0.800 (0.583‐1.098) | .168 |
| CD8 (low vs high) | 0.370 (0.265‐0.518) | .000 | 0.348 (0.249‐0.488) | .000 |
| CD66b (low vs high) | 2.784 (1.981‐3.914) | .012 | 3.137 (2.230‐4.413) | .000 |
| CD68 (low vs high) | 1.764 (1.276‐2.440) | .001 | 1.798 (1.301‐2.484) | .000 |
| Multivariate analysis | ||||
| Sex (female vs male) | 2.171 (1.255‐3.757) | .006 | NA | NA |
| AFP, ng/ml (≤20 vs >20) | NA | NA | 1.328 (0.895‐1.969) | .158 |
| GGT, U/L (≤54 vs >54) | NA | NA | 1.458 (1.024‐2.077) | .037 |
| Tumor size, cm (≤5 vs >5) | 1.783 (1.247‐2.549) | .002 | 1.820 (1.280‐2.587) | .001 |
| Tumor number (single vs multiple) | NA | NA | 1.033 (0.675‐1.579) | .883 |
| Microvascular invasion (no vs yes) | 1.480 (1.048‐2.090) | .026 | 1.680 (1.187‐2.379) | .003 |
| Tumor encapsulation (complete vs none) | 1.302 (0.982‐1.828) | .127 | 1.111 (0.786‐1.570) | .550 |
| Tumor differentiation (I + II vs III +IV) | NA | NA | 1.228 (0.882‐1.711) | .224 |
| TNM stage (I vs II III) | NA | NA | 1.143 (0.867‐1.506) | .345 |
| CD3 (low vs high) | 1.706 (0.493‐1.009) | .056 | 0.673 (0.471‐0.963) | .030 |
| CD8 (low vs high) | 0.297 (0.208‐0.425) | .000 | 0.272 (0.189‐0.390) | .000 |
| CD66b (low vs high) | 3.138 (2.182‐4.514) | .000 | 3.326 (2.306‐4.798) | .000 |
| CD68 (low vs high) | 2.039 (1.422‐2.923) | .000 | 2.391 (1.665‐3.435) | .000 |
Cox proportional hazards regression model. AFP, alpha‐fetoprotein; CI, confidential interval; GGT, gamma glutamyl transferase; HR, hazard ratio; NA, not adopted.